Meagan O’Brien

Meagan O’Brien

Company: Regeneron

Job title: Senior Medical Director

Seminars:

Joint Q&A Session 12:30 pm

Have the speakers answer your questionsRead more

day: Day One

CRISPR/Cas9 Gene Editing in Hemophilia B 9:30 am

A landmark phase 1 clinical trial demonstrated successful gene editing for transthyretin amyloidosis, establishing proof of concept for CRISPR-Cas9 treatment in humans (Intellia Therapeutics and Regeneron Pharmaceuticals) Intellia Therapeutics and Regeneron Pharmaceuticals are developing a targeted insertion platform for the expression of Factor IX from the Albumin locus in liver for the treatment of Hemophilia…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.